These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 9472552

  • 1. Antisense raf oligodeoxyribonucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for gene therapy of radioresistant cancer.
    Gokhale PC, Soldatenkov V, Wang FH, Rahman A, Dritschilo A, Kasid U.
    Gene Ther; 1997 Dec; 4(12):1289-99. PubMed ID: 9472552
    [Abstract] [Full Text] [Related]

  • 2. VP22 light controlled delivery of oligonucleotides to ocular cells in vitro and in vivo.
    Normand N, Valamanesh F, Savoldelli M, Mascarelli F, BenEzra D, Courtois Y, Behar-Cohen F.
    Mol Vis; 2005 Mar 04; 11():184-91. PubMed ID: 15761390
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome.
    Gokhale PC, Zhang C, Newsome JT, Pei J, Ahmad I, Rahman A, Dritschilo A, Kasid UN.
    Clin Cancer Res; 2002 Nov 04; 8(11):3611-21. PubMed ID: 12429653
    [Abstract] [Full Text] [Related]

  • 4. Antisense raf oligodeoxyribonucleotide is a radiosensitizer in vivo.
    Gokhale PC, McRae D, Monia BP, Bagg A, Rahman A, Dritschilo A, Kasid U.
    Antisense Nucleic Acid Drug Dev; 1999 Apr 04; 9(2):191-201. PubMed ID: 10355825
    [Abstract] [Full Text] [Related]

  • 5. Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies.
    Dritschilo A, Huang CH, Rudin CM, Marshall J, Collins B, Dul JL, Zhang C, Kumar D, Gokhale PC, Ahmad A, Ahmad I, Sherman JW, Kasid UN.
    Clin Cancer Res; 2006 Feb 15; 12(4):1251-9. PubMed ID: 16489081
    [Abstract] [Full Text] [Related]

  • 6. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
    Pastorino F, Brignole C, Marimpietri D, Pagnan G, Morando A, Ribatti D, Semple SC, Gambini C, Allen TM, Ponzoni M.
    Clin Cancer Res; 2003 Oct 01; 9(12):4595-605. PubMed ID: 14555535
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of Raf-1 protein kinase by antisense phosphorothioate oligodeoxyribonucleotide is associated with sensitization of human laryngeal squamous carcinoma cells to gamma radiation.
    Soldatenkov VA, Dritschilo A, Wang FH, Olah Z, Anderson WB, Kasid U.
    Cancer J Sci Am; 1997 Oct 01; 3(1):13-20. PubMed ID: 9072302
    [Abstract] [Full Text] [Related]

  • 8. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.
    Pastorino F, Brignole C, Marimpietri D, Di Paolo D, Zancolli M, Pagnan G, Ponzoni M.
    Ann N Y Acad Sci; 2004 Dec 01; 1028():90-103. PubMed ID: 15650235
    [Abstract] [Full Text] [Related]

  • 9. Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer.
    McPhillips F, Mullen P, Monia BP, Ritchie AA, Dorr FA, Smyth JF, Langdon SP.
    Br J Cancer; 2001 Nov 30; 85(11):1753-8. PubMed ID: 11742498
    [Abstract] [Full Text] [Related]

  • 10. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
    Zhang C, Pei J, Kumar D, Sakabe I, Boudreau HE, Gokhale PC, Kasid UN.
    Methods Mol Biol; 2007 Nov 30; 361():163-85. PubMed ID: 17172711
    [Abstract] [Full Text] [Related]

  • 11. Gene expression profile by inhibiting Raf-1 protein kinase in breast cancer cells.
    Mewani RR, Tian S, Li B, Danner MT, Carr TD, Lee S, Rahman A, Kasid UN, Jung M, Dritschilo A, Gokhale PC.
    Int J Mol Med; 2006 Mar 30; 17(3):457-63. PubMed ID: 16465392
    [Abstract] [Full Text] [Related]

  • 12. Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models.
    Mewani RR, Tang W, Rahman A, Dritschilo A, Ahmad I, Kasid UN, Gokhale PC.
    Int J Oncol; 2004 May 30; 24(5):1181-8. PubMed ID: 15067340
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
    Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E, Goldie J.
    Clin Cancer Res; 1999 Oct 30; 5(10):2891-8. PubMed ID: 10537358
    [Abstract] [Full Text] [Related]

  • 15. RAF antisense oligonucleotide as a tumor radiosensitizer.
    Kasid U, Dritschilo A.
    Oncogene; 2003 Sep 01; 22(37):5876-84. PubMed ID: 12947394
    [Abstract] [Full Text] [Related]

  • 16. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.
    Miyake H, Chi KN, Gleave ME.
    Clin Cancer Res; 2000 May 01; 6(5):1655-63. PubMed ID: 10815883
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of hepatic endothelial E-selectin expression by C-raf antisense oligonucleotides blocks colorectal carcinoma liver metastasis.
    Khatib AM, Fallavollita L, Wancewicz EV, Monia BP, Brodt P.
    Cancer Res; 2002 Oct 01; 62(19):5393-8. PubMed ID: 12359742
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
    Lopes de Menezes DE, Hudon N, McIntosh N, Mayer LD.
    Clin Cancer Res; 2000 Jul 01; 6(7):2891-902. PubMed ID: 10914739
    [Abstract] [Full Text] [Related]

  • 20. Tissue distribution of liposome-mediated epidermal growth factor receptor antisense gene therapy.
    Thomas SM, Zeng Q, Dyer KF, Suscovich TJ, Kanter PM, Whalen JD, Watkins SF, Grandis JR.
    Cancer Gene Ther; 2003 Jul 01; 10(7):518-28. PubMed ID: 12833132
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.